SANA
Sana Biotechnology, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -11.8% ·
share flow +16.4% ·
net new positions -13.3%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 49.50K | $139,113 | n/a | n/a |
| Q2 2026 | 85 | +4 | 119.01M | $415.23M | +9 | −5 |
| Q1 2026 | 84 | -3 | 118.01M | $339.95M | +3 | −6 |
| Q4 2025 | 87 | +2 | 116.35M | $473.54M | +2 | n/a |
| Q3 2025 | 15 | -2 | 97.26M | $345.27M | n/a | −2 |
| Q2 2025 | 14 | 0 | 77.71M | $212.16M | +2 | −2 |
| Q1 2025 | 11 | -1 | 31.65M | $53.17M | +1 | −2 |
| Q4 2024 | 12 | -1 | 32.20M | $52.48M | +1 | −2 |
| Q3 2024 | 12 | +2 | 22.88M | $95.19M | +2 | n/a |
| Q2 2024 | 10 | n/a | 23.15M | $126.39M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 37.43M | +10.6% | $132.88M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 2 | Baillie Gifford ✦ | 11.44M | +13.6% | $40.60M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 3 | BlackRock ✦ (passive) | 11.23M | +3.4% | $39.85M | 0.0% | ▲ Add | 2 | SEC ↗ ×11 |
| 4 | The Vanguard Group ✦ (passive) | 9.13M | +19.9% | $32.41M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 5 | State Street Global Advisors ✦ (passive) | 6.68M | +133.6% | $23.72M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 6.55M | +121.7% | $23.26M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | JPMorgan Chase ✦ | 4.27M | n/a | $15.16M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 8 | Geode Capital Management ✦ (passive) | 3.42M | +4.4% | $12.16M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Renaissance Technologies ✦ | 1.99M | +878.1% | $7.07M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | Millennium Management ✦ | 1.62M | +103.1% | $5.75M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 1.18M | -12.9% | $4.20M | 0.0% | ▼ Trim | 5 | SEC ↗ ×5 |
| 12 | Morgan Stanley ✦ | 876.50K | n/a | $3.11M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 13 | Goldman Sachs Group ✦ | 682.09K | n/a | $2.42M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | Two Sigma Investments ✦ | 610.13K | -0.3% | $2.17M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 146.12K | -94.3% | $519,000 | 0.0% | ▼ Trim | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Adage Capital Partners | $1.92M | was 0.0% |
| D. E. Shaw & Co. | $56,762 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 199 holders, 163.30M shares, $468.43M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.